Gene Variant Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Gene RAD51C
Variant E80*
Impact List nonsense
Protein Effect loss of function
Gene Variant Descriptions RAD51C E80* results in a premature truncation of the Rad51c protein at amino acid 80 of 376 (UniProt.org). E80* confers a loss of function to the Rad51c protein as indicated by decreased binding to Rad51b, Xrcc3, and Rad51d in yeast two-hybrid assays (PMID: 14704354).
Associated Drug Resistance
Category Variants Paths

RAD51C mutant RAD51C inact mut RAD51C E80*

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Transcript NM_058216.3
gDNA chr17:g.58695023G>T
cDNA c.238G>T
Protein p.E80*
Source Database RefSeq
Genome Build GRCh38/hg38
Transcript gDNA cDNA Protein Source Database Genome Build
XM_047436505.1 chr17:g.58695023G>T c.238G>T p.E80* RefSeq GRCh38/hg38
XM_017024914.1 chr17:g.58703213G>T c.238G>T p.E80* RefSeq GRCh38/hg38
XM_011525094.3 chr17:g.58703213G>T c.238G>T p.E80* RefSeq GRCh38/hg38
XM_017024919 chr17:g.58703213G>T c.238G>T p.E80* RefSeq GRCh38/hg38
NM_058216 chr17:g.58695023G>T c.238G>T p.E80* RefSeq GRCh38/hg38
XM_017024917.1 chr17:g.58703213G>T c.238G>T p.E80* RefSeq GRCh38/hg38
XM_006722002.5 chr17:g.58695023G>T c.238G>T p.E80* RefSeq GRCh38/hg38
XM_006722004.4 chr17:g.58703213G>T c.238G>T p.E80* RefSeq GRCh38/hg38
XM_006722005.3 chr17:g.58703213G>T c.238G>T p.E80* RefSeq GRCh38/hg38
NM_002876 chr17:g.58695023G>T c.238G>T p.E80* RefSeq GRCh38/hg38
XM_017024916 chr17:g.58703213G>T c.238G>T p.E80* RefSeq GRCh38/hg38
XM_011525093.2 chr17:g.58703213G>T c.238G>T p.E80* RefSeq GRCh38/hg38
XM_017024919.1 chr17:g.58703213G>T c.238G>T p.E80* RefSeq GRCh38/hg38
XM_017024914 chr17:g.58703213G>T c.238G>T p.E80* RefSeq GRCh38/hg38
XM_006722005 chr17:g.58703213G>T c.238G>T p.E80* RefSeq GRCh38/hg38
XM_011525092 chr17:g.58703213G>T c.238G>T p.E80* RefSeq GRCh38/hg38
XM_017024918.2 chr17:g.58703213G>T c.238G>T p.E80* RefSeq GRCh38/hg38
NM_058216.3 chr17:g.58695023G>T c.238G>T p.E80* RefSeq GRCh38/hg38
XM_011525093 chr17:g.58703213G>T c.238G>T p.E80* RefSeq GRCh38/hg38
XM_006722004 chr17:g.58703213G>T c.238G>T p.E80* RefSeq GRCh38/hg38
XM_006722002 chr17:g.58695023G>T c.238G>T p.E80* RefSeq GRCh38/hg38
NM_002876.4 chr17:g.58695023G>T c.238G>T p.E80* RefSeq GRCh38/hg38
XM_006722001.4 chr17:g.58695023G>T c.238G>T p.E80* RefSeq GRCh38/hg38
NM_002876.3 chr17:g.58695023G>T c.238G>T p.E80* RefSeq GRCh38/hg38
XM_017024915.1 chr17:g.58703213G>T c.238G>T p.E80* RefSeq GRCh38/hg38
XM_017024918 chr17:g.58703213G>T c.238G>T p.E80* RefSeq GRCh38/hg38
XM_006722002.4 chr17:g.58695023G>T c.238G>T p.E80* RefSeq GRCh38/hg38
XM_017024916.1 chr17:g.58703213G>T c.238G>T p.E80* RefSeq GRCh38/hg38
XM_017024917 chr17:g.58703213G>T c.238G>T p.E80* RefSeq GRCh38/hg38
XM_006722001 chr17:g.58695023G>T c.238G>T p.E80* RefSeq GRCh38/hg38
XM_011525094.2 chr17:g.58703213G>T c.238G>T p.E80* RefSeq GRCh38/hg38
XM_006722001.5 chr17:g.58695023G>T c.238G>T p.E80* RefSeq GRCh38/hg38
XM_011525094 chr17:g.58703213G>T c.238G>T p.E80* RefSeq GRCh38/hg38
XM_017024915 chr17:g.58703213G>T c.238G>T p.E80* RefSeq GRCh38/hg38
XM_011525092.2 chr17:g.58703213G>T c.238G>T p.E80* RefSeq GRCh38/hg38
NM_058216.2 chr17:g.58695023G>T c.238G>T p.E80* RefSeq GRCh38/hg38
XM_006722004.3 chr17:g.58703213G>T c.238G>T p.E80* RefSeq GRCh38/hg38

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
RAD51C inact mut prostate cancer sensitive Enzalutamide + Talazoparib FDA approved Actionable In a Phase III trial (TALAPRO-2) that supported FDA approval, Talzenna (talazoparib) plus Xtandi (enzalutamide) improved median radiographic progression-free survival compared to enzalutamide plus placebo (27.9 vs 16.4 mo, HR 0.46, p=0.0003) in patients with metastatic castration-resistant prostate cancer harboring deficient homologous recombination repair genes including RAD51C, HR was 0.66 (p=0.12) in patients with non-BRCA mutations treated with Talzenna (talazoparib) (PMID: 37285865; NCT03395197). 37285865 detail...
RAD51C inact mut prostate cancer sensitive Enzalutamide + Talazoparib Guideline Actionable Talzenna (talazoparib) plus Xtandi (enzalutamide) is included in guidelines as systemic therapy for patients with metastatic castration-resistant prostate cancer harboring a pathogenic germline or somatic RAD51C mutation who have not been treated in the setting of castration-resistant prostate cancer (NCCN.org). detail...
RAD51C inact mut prostate cancer sensitive Olaparib FDA approved - On Companion Diagnostic Actionable In a Phase III trial (PROfound) that supported FDA approval, Lynparza (olaparib) treatment significantly improved median imaging-based progression-free survival (5.8 vs 3.5 mo, HR 0.49, p<0.001) compared to control in patients with metastatic castration-resistant prostate cancer who progressed on hormone therapy and harbored deleterious or suspected deleterious mutations in homologous recombination repair genes, including RAD51C (PMID: 32343890; NCT02987543). detail... detail... 32343890
RAD51C inact mut prostate cancer sensitive Olaparib Guideline Actionable Lynparza (olaparib) is included in guidelines as second-line therapy post androgen receptor-directed therapy for patients with metastatic castration-resistant prostate cancer harboring pathogenic mutations in RAD51C (NCCN.org). detail...
RAD51C inact mut ovarian cancer predicted - sensitive RP-3500 Case Reports/Case Series Actionable In a Phase I/II trial (TRESR), RP-3500 treatment resulted in a partial response with complete resolution of the target lesion at 19 weeks in a patient with ovarian cancer harboring a RAD51C inactivating mutation (PMID: 37277454; NCT04497116). 37277454
RAD51C inact mut Advanced Solid Tumor sensitive E7449 Preclinical Actionable In a preclinical study, E7449 inhibited proliferation of a RAD51C-deficient cell line in culture, which demonstrated increased sensitivity compared to cells without DNA repair pathway mutations (PMID: 26513298). 26513298
RAD51C mutant ovarian serous carcinoma predicted - sensitive Olaparib Case Reports/Case Series Actionable In a clinical case study, Lynparza (olaparib) treatment resulted in a complete response with treatment ongoing at 14 months in a patient with relapsed, metastatic high grade serous ovarian carcinoma harboring RAD51C mutations (PMID: 36176748). 36176748
RAD51C mutant breast cancer not applicable N/A Guideline Risk Factor Germline RAD51C mutations are associated with increased risk of developing breast cancer (NCCN.org). detail...
RAD51C mutant ovarian cancer not applicable N/A Guideline Risk Factor Germline RAD51C mutations are associated with increased risk of developing ovarian cancer (NCCN.org). detail...